Pyrano[2,3-b]chromone derivatives as novel dual inhibitors of α-glucosidase and α-amylase: Design, synthesis, biological evaluation, and in silico studies
| dc.contributor.author | Farzaneh, Elnaz | |
| dc.contributor.author | Mohammadi, Mohammad | |
| dc.contributor.author | Raymand, Pooya | |
| dc.contributor.author | Noori, Milad | |
| dc.contributor.author | Golestani, Sahand | |
| dc.contributor.author | Ranjbar, Sara | |
| dc.contributor.author | Ghasemi, Younes | |
| dc.date.accessioned | 2025-10-18T10:11:02Z | |
| dc.date.created | 2024 | |
| dc.date.issued | 2024 | |
| dc.department | Bartın Üniversitesi | |
| dc.description.abstract | Inhibition of alpha-glucosidase and alpha-amylase is an important target for treatment of type 2 diabetes. In this work, a novel series of pyrano[2,3-b]chromene derivatives 5a -m was designed based on potent alpha-glucosidase and alpha-amylase inhibitors and synthesized by simple chemical reactions. These compounds were evaluated against the latter enzymes. Most of the title compounds exhibited high inhibitory activity against alpha-glucosidase and alpha-amylase in comparison to standard inhibitor (acarbose). Representatively, the most potent compound, 4methoxy derivative 5d, was 30.4 fold more potent than acarbose against alpha-glucosidase and 6.1 fold more potent than this drug against alpha-amylase. In silico molecular modeling demonstrated that compound 5d attached to the active sites of alpha-glucosidase and alpha-amylase with a favorable binding energies and established interactions with important amino acids. Dynamics of compound 5d also showed that this compound formed a stable complex with the alpha-glucosidase active site. In silico drug-likeness as well as ADMET prediction of this compound was also performed and satisfactory results were obtained. | |
| dc.identifier.doi | 10.1016/j.bioorg.2024.107207 | |
| dc.identifier.issn | 0045-2068 | |
| dc.identifier.issn | 1090-2120 | |
| dc.identifier.pmid | 38402795 | |
| dc.identifier.scopus | 2-s2.0-85186247078 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://doi.org/10.1016/j.bioorg.2024.107207 | |
| dc.identifier.uri | https://hdl.handle.net/11772/22174 | |
| dc.identifier.volume | 145 | |
| dc.identifier.wos | WOS:001203604100001 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Academic Press Inc Elsevier Science | |
| dc.relation.ispartof | Bioorganic Chemistry | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.relation.sdg | Goal-03: Good Health and Well-Being | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | WoS_20251016 | |
| dc.subject | Pyrano[2,3-B]Chromene | |
| dc.subject | Alpha-Glucosidase | |
| dc.subject | Alpha-Amylase | |
| dc.subject | Docking | |
| dc.subject | Admet | |
| dc.subject | Diabetes | |
| dc.title | Pyrano[2,3-b]chromone derivatives as novel dual inhibitors of α-glucosidase and α-amylase: Design, synthesis, biological evaluation, and in silico studies | |
| dc.type | Article | |
| dspace.entity.type | Publication |










